Ventilator-associated pneumonia
Ventilator-associated pneumonia (VAP) is among the most common and lethal ICU-acquired infections, and Pseudomonas aeruginosa is a leading cause associated with high attributable mortality, prolonged ventilation, and frequent treatment failure. The pathogen's intrinsic and acquired multidrug resistance, its propensity to form biofilms on endotracheal tubes and within the airway, and the dwindling antibiotic pipeline make P. aeruginosa VAP a textbook target for alternative therapeutics. Lytic bacteriophages are attractive here because they self-amplify at the site of infection, kill only the target species (sparing the lung and gut microbiome), penetrate biofilm, and remain active against strains resistant to all available antibiotics. Crucially, the airway is directly accessible for nebulized or intratracheal delivery, allowing high local phage titers without systemic exposure.
How phages act here
Mechanism
Phages bind strain-specific surface receptors on P. aeruginosa (LPS, type IV pili, flagella), inject their genome, hijack host machinery to replicate, and lyse the cell, so cocktails of several phages with complementary receptor specificities are used to broaden coverage and suppress resistance. Many anti-Pseudomonas phages encode depolymerases that degrade exopolysaccharide and disrupt the biofilm matrix that shields organisms on endotracheal tubes, improving access to embedded cells and to co-administered antibiotics. Phage-antibiotic synergy is a central theme: in a 2025 murine VAP model (Weissfuss et al.), phages produced a rapid ~4-log kill while meropenem sustained suppression and prevented resistant-clone outgrowth, and the combination achieved therapeutic effect at roughly 10-fold lower antibiotic concentrations while avoiding the antibiotic-induced release of epithelium-damaging virulence factors. Resistance can arise via receptor mutation, but this often imposes a fitness or virulence cost (e.g., loss of LPS or efflux-pump-linked receptors can re-sensitize bacteria to antibiotics), and engineered or CRISPR-armed phages are an active research direction to expand host range and program lethality.
Where it stands
Current evidence
Evidence for P. aeruginosa VAP specifically is still early-stage (preclinical and emerging clinical), though the broader pulmonary-Pseudomonas phage field is advancing. The strongest mechanistic VAP data come from Weissfuss et al., Nature Communications 2025, showing adjunctive phage plus meropenem outperformed either monotherapy in a mechanically ventilated mouse model of P. aeruginosa pneumonia. The first dedicated randomized controlled trial in true VAP, NCT07202234 (Chinese PLA General Hospital), is a ~248-patient study of a nebulized phage cocktail (twice daily) versus saline for MDR Gram-negative VAP including P. aeruginosa, with start late 2025 and completion estimated 2028. For pulmonary P. aeruginosa more broadly, Armata Pharmaceuticals reported positive Phase 2 Tailwind results (December 2024) for inhaled AP-PA02, with statistically significant lung CFU reductions in non-CF bronchiectasis, validating inhaled phage delivery to the lung. The historic PhagoBurn RCT (Jault et al., Lancet Infect Dis 2019) established safety of an anti-Pseudomonas cocktail but underdosed phage, an instructive cautionary precedent. Numerous compassionate-use case reports of phage therapy for P. aeruginosa respiratory infection also exist. Overall: no approved product, but multiple registered trials and a maturing inhaled-delivery platform.
Evidence confidence: medium
The data
Key studies & trials
- Weissfuss C, Kneib N, Bischoff P, et al. Adjunctive phage therapy improves antibiotic treatment of ventilator-associated-pneumonia with Pseudomonas aeruginosa. Nature Communications. 2025;16:4500. PMID: 40368965. ↗
- Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infectious Diseases. 2019;19(1):35-45. PMID: 30292481. ↗
- Chinese PLA General Hospital. A Randomized Controlled Trial of Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia (nebulized phage cocktail vs saline; MDR Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa). ClinicalTrials.gov identifier NCT07202234; registered 2025, est. completion 2028. ↗
- Armata Pharmaceuticals. Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection — positive topline results announced December 2024 (significant lung P. aeruginosa CFU reduction). ↗
Who is working on it
Programs & centers
The possibility
Within the next several years, intubated patients colonized with pan-resistant Pseudomonas could plausibly receive a nebulized phage cocktail at the bedside as a precision adjunct to antibiotics, matched to their isolate by a same-day phagogram and chosen to re-sensitize the bacteria even as it kills them. As inhaled delivery is validated (AP-PA02) and the first dedicated VAP RCT reads out, phages may shift from heroic last-resort compassionate use to a standardized, microbiome-sparing tool that shortens ventilation and curbs resistance. The longer horizon — engineered and depolymerase-armed phages that strip biofilm off the endotracheal tube and CRISPR-guided constructs that program lethality — points toward turning one of the ICU's deadliest infections into a treatable one.